STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

Dasatinib

Also known as

Sprycel · BMS-354825 · Phyrago (dasatinib tablets brand discussed in PK notes) · D+Q (with quercetin) · DQ / D&Q senolytic pair · Dasatinib + quercetin senolytic pair · Intermittent dasatinib (senolytic pulse talk)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Some talk Systemic Oral Senolytic & longevity compounds

Systemic oral multi-kinase (BCR-ABL / Src-family) small molecule.

What people say Dasatinib is a prescription oral tyrosine-kinase inhibitor approved for specific leukemias. Longevity discussion usually means intermittent D+Q, not standalone dasatinib, and the early senolytic studies do not create an approved anti-aging use. Doses people talk about
Community spacing and amounts100 mg D + about 1000–1500 mg Q for 2–3 days, repeated from weeks to months apart

Inspected forum examples include every-other-month and quarterly clusters; products, co-agents and calendars are unverified.

Senolytic dasatinib unit100 mg oral once daily on each on-day

Near-universal adult dasatinib amount in the cited D+Q human pilots; not an approved aging dose.

Quercetin pairing1000 mg/day, often 500 mg twice daily, or 1250 mg/day

The co-agent amount and product form differ across DKD and IPF programs; it is not dasatinib monotherapy.

Three-day study blockD 100 mg + Q 1000–1250 mg daily for 3 consecutive days

Used as a single DKD course and as repeated blocks in other small programs and forum copies.

Two-day study blockD 100 mg + Q 1000 or 1250 mg daily for 2 consecutive days

Appears in AD-family and mental-health pilot calendars with distinct repeat spacing.

Animal referenceAbout 5 mg/kg D + 50 mg/kg Q intermittently

Mouse-study amount and route context; not a human conversion.

Oncology contrastContinuous daily oral dosing; 100 mg once daily is one historical adult CML starting regimen

Different indication, duration, interaction management and monitoring from experimental senolytic pulses.

These are historical community, study and label amounts, not a progression ladder. Formulation, disease population, interactions and monitoring make equal milligrams non-equivalent in risk. Oral use is described with or without food; a high-fat meal raised mean AUC about 14% in the label. Acid suppression and CYP3A4 modifiers can cause larger exposure changes. Study spacing examples: One course; 3 days/week for 3 weeks; 2 days about every 2 weeks; monthly 3-day blocks. Different condition-specific study designs over weeks to months; they are not interchangeable healthy-user schedules.

Half-life & effect duration

Half-life in the body
  • Oral tabletsAbout 3–5 hours
Felt duration people report
  • D+Q accountsNo effect, about a day of fatigue, or several days of nausea, headache, feverishness or brain fog
Timing context & sources
How it may feel Intermittent D+Q accounts range from no obvious effect to nausea, diarrhea, headache, fatigue or flu-like malaise during a pulse, with some people claiming delayed benefits. That experience is not comparable to years of continuous oncology dosing and monitoring.
Cycles people discuss Exploratory senolytic studies use short oral on-blocks and long off-periods: one three-day course, three days per week for three weeks, two days about every two weeks, or monthly three-day blocks. Community variants extend further, without a settled lifelong cadence. Timing Intermittent D+Q discussion commonly puts the dasatinib tablet in one morning on-day amount; twice-daily splits usually refer to quercetin. The retained oncology label permits food or no food. These contexts are not interchangeable treatment instructions. Stacks Quercetin is the core senolytic co-agent; fisetin, rapamycin, metformin and NAD-related supplements appear around it in longevity charts. These combinations complicate interaction risk and make personal outcome attribution weak. Watch for Myelosuppression (label): Neutropenia, thrombocytopenia, anemia — core oncology risk; intermittent use lowers total exposure vs years of daily dosing but does not make counts irrelevant.
Related
QuercetinFisetinFOXO4-DRIMetforminNMN

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Current oral dasatinib labeling reports a mean terminal half-life of about 3–5 hours.

Peak concentrations occur variably from 0.5 to 6 hours after oral dosing. Dasatinib is primarily metabolized by CYP3A4, making exposure interaction-sensitive.

This parent-drug pharmacokinetic clock does not measure senescent-cell clearance, quercetin, biopsy timing or the duration of any claimed benefit. Oncology label safety cannot be erased by intermittent use.

  • DailyMed — Dasatinib tablets full prescribing information (opens in a new tab)Clinical Pharmacology and safety sections: oral Tmax 0.5–6 hours, mean terminal half-life 3–5 hours, CYP3A4 metabolism, food and gastric-pH interaction effects, and labeled serious toxicities.Prescription oncology labeling for dasatinib; no approved anti-aging use and no quercetin or healthy-longevity outcome clock.

Felt duration people report

Intermittent D+Q accounts do not establish one typical felt duration: some report no effect, some roughly one day of fatigue, and others several days of nausea, feverishness, headache, fatigue or brain fog.

The relevant longevity reports co-administered quercetin and often other agents, so they describe D+Q experiences rather than a clean standalone dasatinib challenge.

Unverified products, co-agents, disease status and calendars differ. Subjective persistence is not parent-drug half-life, and delayed benefit claims are not proof of a senolytic mechanism.

Other context in this card

What people say 11

  • Complementary SCAPs: Community and reviews stress D alone or Q alone are weaker senolytics than the pair for broad tissue coverage. forum
  • Subjective “reset”: Some self-experiment logs describe flu-like pulse days then better energy/recovery weeks later — highly confounded by quercetin form, lifestyle, and expectation. anecdote
  • DKD pilot (Mayo, Hickson 2019): Open-label N=9 diabetic kidney disease; single 3-day oral D 100 mg/day + Q 1000 mg/day (500 mg BID); adipose and skin biopsies ~11 days later showed lower senescent-cell markers (p16, p21, SAβ-gal) and circulating SASP factors vs baseline. trial
  • IPF open-label pilot (Justice et al.): D 100 mg/day + Q 1250 mg/day, 3 consecutive days/week × 3 weeks (9 doses); physical function signals including ~21.5 m mean 6-minute walk distance gain and better gait/chair-stand metrics in a small IPF cohort — condition-specific, not general longevity proof. trial
  • IPF randomized pilot (Nambiar 2023): Blinded D 100 mg/d + Q 1250 mg/d (phytosome product in protocol), 3 consecutive days/week × 3 weeks vs placebo; feasibility/tolerability focus; function endpoints exploratory and mixed. trial
  • Bone phase 2 (Farr 2024, N=60 postmenopausal): Intermittent D+Q over 20 weeks; primary CTx (resorption) at 20 weeks did not beat control overall; P1NP (formation) rose early (+~16% vs control at 2 and 4 weeks) then not different at 20 weeks; exploratory high T-cell p16 tertile subgroup gained formation, cut resorption early, and +~2.7% radius BMD at 20 weeks — response may track senescence burden. trial
  • SToMP-AD pilot (Gonzales 2023): Early AD N=5; intermittent D+Q over ~12 weeks (2 days on / ~14 days off × 6 cycles); regimen appeared safe/tolerable; dasatinib detected in CSF in most; quercetin not detected in CSF; no clear cognitive or AD-biomarker win in this tiny open sample. trial
  • SToMP-AD / Wake Forest-style ongoing design talk: Common template 100 mg D + 1000 mg Q for 2 consecutive days every ~15 days × 6 cycles over 12 weeks (placebo-controlled cognitive-aging designs discussed publicly). trial
  • Animals (multi-lab): Intermittent D+Q (often ~5 mg/kg D + ~50 mg/kg Q in mice, oral gavage or IP depending on study) reduces senescent burden and improves aging-related phenotypes across adipose, disc, bone, kidney, and some neurodegeneration models; results model-dependent. animal
  • Disc degeneration mice: Weekly long-term D+Q delayed age-related intervertebral disc degeneration; in SM/J severe-degeneration models D+Q outperformed navitoclax on histology/senescence markers in at least one head-to-head. animal
  • What is not shown: No large RCT proving healthy-adult healthspan or lifespan benefit; intermittent ≠ proven risk-free. trial

Doses people talk about 17

  • Community spacing variants: Off 11–28 days; monthly 2–3 day blocks; every other month; quarterly “3 weeks of weekly pulses then long break”; some combine rapamycin weekly with D+Q every 1–2 months. forum
  • Forum self-report examples (anecdotal, not evidence): 100 mg D + ~1000–1500 mg Q for 2–3 days; one multi-year log: 100 mg D + 1.5 g Q, 3 days/week × 3 weeks every 4–5 months; another: 100 mg D + 1200 mg Q two consecutive days every other month. anecdote
  • Source form: Prescription film-coated tablets (Sprycel/generic) vs gray-market “research” tablets — community warns quality and legality diverge sharply. forum
  • Quercetin co-dose A: 1000 mg/day total, often as 500 mg twice daily (Mayo DKD Hickson protocol). trial
  • Quercetin co-dose B: 1250 mg/day oral (common IPF Justice/Nambiar-style protocols; sometimes phytosome/phospholipid complex product specified). trial
  • Pulse length A — 3-day block: D 100 mg + Q 1000–1250 mg daily for 3 consecutive days (DKD single course; many forum copies; bone trial 3-day blocks). trial
  • Pulse length B — 2-day block: D 100 mg + Q 1000 mg (or 1250 mg) daily for 2 consecutive days (SToMP-AD family; mental-disorder pilot protocol uses 2 days). trial
  • Acid suppression: Antacids should be separated (often ≥2 hours before/after); PPIs/H2 blockers can reduce dasatinib exposure via gastric pH — major practical interaction many self-experiment writeups under-specify. trial
  • CYP3A4: Strong inhibitors raise dasatinib levels (toxicity risk); strong inducers lower them; grapefruit/St. John’s wort style lists appear in oncology counseling and should not be ignored in intermittent use either. trial
  • Quercetin form variable: Aglycone powder/caps vs phytosome/phospholipid complexes used in some trials — bioavailability not interchangeable 1:1. trial
  • Framing: Research/community ranges only — not medical advice, not a prescription, not an approved aging dose. forum
  • Core senolytic D dose (human trials): 100 mg oral dasatinib once daily on each on-day — the near-universal adult unit in published D+Q pilots. trial
  • Spacing / cycle examples (trials): Single one-time 3-day course; 3 days/week × 3 consecutive weeks (IPF); 2 days on / ~13–14 days off × 6 cycles over 12 weeks (AD pilots); every ~28 days × ~5 three-day blocks over 20 weeks (bone phase 2); 2 days on / 5 days off weekly for several weeks (mental-health protocol: D 100 + Q 1250). trial
  • Fixed adult mg, not mg/kg: Human protocols almost never weight-adjust the 100 mg D tablet unit; animal work is mg/kg. trial
  • Animal reference (not human conversion): Common mouse regimen ~5 mg/kg dasatinib + ~50 mg/kg quercetin, intermittent (e.g. 3 consecutive days every 2 weeks, or weekly IP/oral depending on lab). animal
  • Oncology contrast (label context): Continuous daily oral dasatinib for CML (adult chronic-phase starting doses historically include 100 mg once daily among labeled regimens) — different intent, duration, and monitoring. trial
  • Food: Label allows with or without food; high-fat meal ~14% mean AUC increase after 100 mg single dose — usually called not clinically major for oncology, still discussed. trial

How it may feel 7

  • On pulse days (1–2 or 1–3): GI upset, nausea, loose stool, headache, fatigue, mild flu-like malaise more common than any “younger” feel; some barely notice. forum
  • Immediate post-pulse (days 1–7 after last dose): Mainly side-effect recovery window; subjective benefit often not claimed yet. anecdote
  • Off weeks: Dominant lived experience is long drug-free stretches — no continuous daily “kinase feel.” forum
  • Months 1–3 multi-cycle: Self-experimenters reassess energy, recovery, labs, and whether schedule is worth repeating; attribution is weak. forum
  • Long open-ended pulses: Multi-year intermittent logs exist on longevity forums (e.g. 2–3 day blocks every 1–2 months or quarterly clusters) with many “no obvious effect” reports alongside positive anecdotes. anecdote
  • ~1–2 weeks post-pulse: Trial biopsy timing (e.g. ~11 days after last dose in DKD pilot) is why forums talk about lag before any “clearance” narrative. trial
  • Vs continuous CML dosing: Daily Sprycel for years is a completely different lived toxicity and monitoring profile (fluid retention, cytopenias, etc.). trial

Cycles people discuss 9

  • Why the off period: Clear senescent cells over days–weeks; avoid continuous kinase inhibition and accumulate recovery between pulses. forum
  • Open-ended community use: Some continue intermittent pulses for years without a validated healthy-user safety dataset. forum
  • No settled lifelong cadence: Frequency is copied from small trials or personal preference; re-challenge after long gaps is common. forum
  • Dominant pattern: Short on-block (2–3 days D+Q) then multi-week off — “hit-and-run” senolytic logic, not chronic daily TKI. trial
  • One-shot pilot: Single 3-day course with biomarker/biopsy follow-up ~11 days later (DKD). trial
  • Compressed 3-week IPF style: 3 consecutive dosing days each week for 3 weeks (9 total D+Q days). trial
  • Biweekly AD style: 2 days on / ~2 weeks off for ~6 cycles (~12 weeks). trial
  • Monthly bone style: 3-day blocks about every 28 days for ~20 weeks (~5 pulses). trial
  • Weekly clustered mental-health protocol example: 2 consecutive days D+Q at baseline and weeks 1–3 (2 on / 5 off) with later follow-up assessments. trial

Timing 8

  • Why short t½ still used intermittently: Community/trial logic is acute SCAP inhibition kills senescent cells; effect is not thought to require steady-state plasma levels like chronic CML control. forum
  • Timing habit: Once-daily morning full on-day dose for 2–3 consecutive days is the usual discussed pattern; BID applies to quercetin splits, not typically to the 100 mg D tablet. forum
  • Terminal half-life: Mean ~3–5 hours after oral clinical doses (label/PK literature). trial
  • Tmax: Roughly 0.5–6 hours post-dose (variable). trial
  • Metabolism: Primarily CYP3A4 (plus other pathways); exposure highly interaction-sensitive. trial
  • Food effect: Modest AUC bump with high-fat meal (~14% at 100 mg); may be taken with or without meals per oncology labeling. trial
  • CNS: Small AD pilot detected low-level dasatinib in CSF post-dose in most participants; quercetin was not detected in CSF — relevant to brain-senolytic debates. trial
  • Downstream lag: Biopsy and subjective checkpoints often ~1–2+ weeks after the last on-day, not at Cmax. trial

More on what it is 7

  • Why people care: First practical dual senolytic combo widely discussed after Kirkland/Mayo mouse work and early human D+Q pilots showing lower senescent-cell markers after short courses. forum
  • Hit-and-run idea: Brief multi-day exposure is claimed to kill long-lived senescent cells; weeks off allow clearance and recovery without chronic kinase block. forum
  • With quercetin almost always: Longevity claims and protocols are D+Q; solo dasatinib as a lifestyle senolytic is rarely the discussed regimen. forum
  • What it is: Oral tyrosine-kinase inhibitor (brand Sprycel; BMS-354825) approved for Ph+ CML/ALL; in longevity talk it is one half of the D+Q senolytic pair. trial
  • Mechanism talk: Dasatinib hits Src/tyrosine-kinase survival paths in some senescent cell types; quercetin is said to hit others (e.g. Bcl-xL / flavonoid SCAPs); together they cover more SCAP networks than either alone. animal
  • Evidence honesty: Human aging data are early/small/open-label or mixed RCTs; oncology label safety literature is dense and continuous-use. No approved anti-aging indication. trial
  • Not this: Not a peptide, not fisetin alone, not navitoclax, not FOXO4-DRI; pulse D+Q is not the same risk/exposure profile as years of daily Sprycel. trial

Stacks 9

  • D+Q+F: Some add fisetin (another flavonoid senolytic) in self-protocols or sequential glioma/aging trial concepts — not a single standardized triple. forum
  • Metformin / NMN–NR / spermidine / exercise / sleep / protein: Listed beside D+Q in “stack charts,” not as proven synergy. forum
  • vs fisetin-only: Fisetin positioned as natural single-agent alternative when people want to avoid a TKI — different evidence and dose culture. forum
  • vs FOXO4-DRI: Peptide research senolytic with different selectivity story; D+Q wins on oral access, cost, and human pilot volume. forum
  • Lifestyle after pulse: Training and sleep often credited for any “better recovery” weeks later — confounded. anecdote
  • D+Q (core): Dasatinib + quercetin — the default human senolytic pair in pilots and forums; almost never “D alone” for aging talk. trial
  • D+Q dose pairings people cite: 100 mg D + 1000 mg Q/day or 100 mg D + 1250 mg Q/day on on-days; Q often split BID when total is 1000 mg. trial
  • Near rapamycin / sirolimus: Common longevity-stack neighbor (senomorphic vs senolytic framing); concurrent use confounds attribution and raises interaction vigilance (sirolimus is a CYP3A/narrow-therapeutic-range example called out in trial exclusions). forum
  • vs navitoclax (ABT-263): Other BCL-family senolytic with heavier thrombocytopenia lore; mouse disc work sometimes favors D+Q over navitoclax — not a human head-to-head. animal

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 17

  • Pulse-window common (community + small trials): Nausea, diarrhea, headache, fatigue, mild flu-like symptoms during multi-day D+Q blocks; usually self-limited in short courses. forum
  • Rx / legality / monitoring: Off-label oncology tablets without physician oversight, CBC, and comorbidity review is a repeatedly flagged serious issue. forum
  • Gray market: Counterfeit or research-only supply chains add purity and dose uncertainty on top of pharmacology risk. forum
  • Myelosuppression (label): Neutropenia, thrombocytopenia, anemia — core oncology risk; intermittent use lowers total exposure vs years of daily dosing but does not make counts irrelevant. trial
  • Fluid retention / pleural effusion (label): Major labeled caution with continuous therapy (all-grade pleural effusion common in long CML follow-up; grade 3/4 less common but serious). Watch dyspnea, cough, chest pain, swelling, rapid weight gain. trial
  • Bleeding / hemorrhage (label): Especially with low platelets; GI and other bleeds reported in oncology use. trial
  • Pulmonary arterial hypertension signal (label): Rare but serious; stop and evaluate unexplained dyspnea in labeled practice. trial
  • Cardiovascular events (label): Ischemia, conduction issues, cardiac-related fluid retention discussed in oncology safety. trial
  • Infection risk: Via cytopenias and general kinase-inhibitor immune context — active infection is a common trial exclusion vibe. trial
  • CYP3A4 interactions: Strong inhibitors (e.g. certain azoles, macrolides, ritonavir-type) can spike levels; strong inducers (e.g. rifampin, carbamazepine, St. John’s wort) can crash exposure; trial protocols exclude many narrow-therapeutic-range substrates/inducers/inhibitors. trial
  • Acid-reducing agents: PPIs/H2 blockers may cut absorption; separate antacids by ~2 hours — under-discussed in casual forum stacks. trial
  • Pregnancy / fetal harm: Labeled fetal risk — avoid in pregnancy; contraception counseling is standard oncology practice. trial
  • Intermittent ≠ zero risk: Short courses in small pilots report mostly mild AEs and rare SAEs in selected populations, but healthy long-term self-experiment safety is not established. trial
  • Bone RCT note: No serious adverse events observed in the 20-week postmenopausal intermittent D+Q trial (N=60) — still not a free pass for unsupervised use. trial
  • Avoid / high-caution contexts discussed: Pregnancy, active infection, significant cytopenias, uncontrolled cardiopulmonary disease, recent major surgery/bleeding risk, strong interacting meds, and stacking with other myelosuppressive or effusion-prone drugs without expertise. trial
  • Young healthy animal caution (discussed): Some mouse work reported adverse metabolic/cognitive signals from D+Q in young females — used in forums as a “don’t pulse if young and low senescence burden” talking point, not a human rule. animal
  • Sparse honesty: Large, long, healthy-volunteer intermittent-safety RCTs are still missing; most human efficacy signals remain early, disease-specific, or exploratory-subgroup. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →